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Abstract: Vincristine sulfate is one of the most effective chemical agents used in canine transmissible venereal tumor (CTVT)
chemotherapy. Its therapeutic effectiveness is pronounced and significant at the beginning of treatment. The present study was designed
to investigate vincristine sulfate treatment and the relationship between CTVT tumor regression and apoptosis [estimated by TdTmediated dUTP-biotin nick end labeling (TUNEL)], galectin-3 (H-160), Bcl-2 (N-9), and lectin [EEL (B-135), GSL I (L-1100), and
RCA I (BA-0084)] expression using immunohistochemical staining in 20 bitches with naturally occurring CTVTs. Evaluation was
semiquantitatively performed by HSCORE values using light microscopy. All observed staining was intracytoplasmic and increased
endothelial staining was noted with the Bcl-2 marker in tumor vessels. Apoptosis, TUNEL, and lectin scoring was higher in vincristine
sulfate-treated tumors than in untreated tumors, while expression of antiapoptotic factors galectin-3 and Bcl-2 were lower in treated
than in untreated CTVTs. These results show that galectin-3, Bcl-2, and lectins (EEL, GSL-1, and RCA-1) are suitable indicators/markers
for CTVT tumor regression after treatment with vincristine sulfate.
Key words: Transmissible venereal tumor, Bcl-2, galectin-3, vincristine sulfate, TUNEL, immunohistochemistry, lectins

1. Introduction
Canine transmissible venereal tumors (CTVTs) are most
commonly found on the external genital organs. The
tumor is spread in healthy dogs by direct contact with
injured skin or mucous tissue (1). CTVTs are observed
most often in young, stray dogs, particularly sexually
active and intact dogs, and have been reported worldwide.
Several treatment options are available for the tumor,
although chemotherapy is considered the most effective
(2). Vincristine sulfate is considered to be an efficient
chemotherapeutic agent and complete remission can be
expected. Regression of tumors is associated with the
presence of large numbers of lymphocytes, plasma cells,
and activated macrophages in the regressing tumors,
suggesting a role for localized antibody-mediated control
of CTVT and making vincristine sulfate a drug of choice.
The Bcl-2 gene is a member of a rapidly expanding
family of genes that regulates apoptosis and can be
functionally characterized as an apoptosis-suppressing
* Correspondence: ozyigit@uludag.edu.tr

factor (3). It has been observed that CTVT samples
overexpressed the Bcl-2 protein independent of the stage
of tumor development (1). Galectin-3, a nonintegrin
β-galactoside-binding lectin, seems to play an important
role in cellular adhesion, inflammation, inhibition of
apoptosis, and malignant transformation of tissue and
cells (4). The present study was conducted to investigate
the relationship between CTVT tumor regression by
apoptosis in dogs treated with vincristine sulfate and the
expression of galectin-3, Bcl-2, and lectins (EEL, GSL-I,
RCA-I) as detected by immunohistochemical staining in
regressing tumors.
2. Materials and methods
2.1. Tumor material
A total of 20 bitches, 2–12 years old (4.05 ± 0.52 years)
and with naturally occurring CTVTs, were investigated at
a local kennel (Karacabey, Bursa, Turkey) and the Faculty
of Veterinary Medicine of Uludağ University (Bursa,
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Turkey). During the treatment period, the dogs were kept
in Karacabey under uniform management conditions and
were fed commercial feed and water ad libitum. CTVT was
diagnosed and confirmed by clinical signs and cytological
procedures. Throughout the treatment period, blood
samples were taken from the cephalic vein of all dogs for
hematological examination prior to the introduction of
chemotherapy. Hematological examination was performed
with an Abbott Cell-Dyn 3500 hematological analyzer
(GML Inc., USA). Chemotherapy was discontinued when
the packed cell volume (PCV) was less than 25% and the
leukocyte count was below 3000/µL, when normal values
were observed. For chemotherapy, vincristine sulfate
(Vincristine DBL, Mayne Pharma Pty Ltd., Australia)
was administered weekly as an infusion for 3 min via the
intravenous route at a dose of 0.025 mg/kg after dilution
with physiologic saline to a total volume of 10 mL.
Treatment was continued until the total remission of the
tumor or for a maximum period of 7 weeks. Before each
vincristine sulfate application, the dogs were reevaluated
clinically and macroscopically. Absence of growth in the
vagina was considered as the recovery point. The tumor
samples were collected prior to the first vincristine
treatment (untreated samples) and after treatment with
vincristine sulfate (treated samples). Treated tumor biopsy
samples were collected 7 days after the first vincristine
sulfate application. Both control and treated tumor
samples were fixed overnight in 10% neutral phosphatebuffered formalin, dehydrated through a graded ethanol
series, and then embedded in paraffin blocks and cut to 4
µm in thickness using a rotary microtome.
2.2. TUNEL for apoptosis
Specimen sections with a thickness of 4 µm were
deparaffinized in xylene and rehydrated in graded alcohol
(70%–100%). Apoptosis was detected by the TdT-mediated
dUTP-biotin nick end labeling (TUNEL) method using
the ApopTag Peroxidase In Situ Apoptosis Detection
Kit (S7100; Chemicon International, USA). The tissue
sections were fixed in 1% paraformaldehyde [in phosphate
buffered saline (PBS), pH 7.4] for 10 min at room
temperature, washed twice in PBS for 5 min, and refixed
in precooled ethanol/acetic acid (2/1) for 5 min at –20 °C.
Thereafter, the sections were incubated with 3% H2O2 for
5 min at room temperature followed by a wash with PBS
(2 × 5 min). Sections were incubated with equilibration
buffer for at least 10 min at room temperature and then
with working-strength TdT enzyme at 37 °C for 60 min,
at which point the sections were agitated for 15 s at room
temperature and then incubated for 10 min with working
strength stop/wash buffer, followed by a wash with
PBS (2 × 1 minute). Sections were then incubated with
antidigoxigenin conjugate for 30 min at room temperature
followed by a wash with PBS (4 × 2 minutes). Sections
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were stained with 3,3’-diaminobenzidine (DAB) solution,
dehydrated, and mounted.
2.3. Galectin-3 and Bcl-2 immunohistochemistry
Sections of specimens were deparaffinized in xylene
and rehydrated in graded alcohol (70%–100%). Slides
were subjected to treatment with boiling water with 10%
antigen retrieval solution (10 mM citrate buffer pH 6.0,
LabVision, USA) followed by a 0.3% methanol-H2O2
solution for 30 min. After washing 3 times with PBS, the
tissues were treated with 2% bovine albumin serum (BSA,
Sigma) for 30 min to prevent nonspecific binding and
then were incubated with antibodies to galectin-3 (H-160,
Santa Cruz Biotechnology, USA) and Bcl-2 (N-9, Santa
Cruz Biotechnology), each diluted to 1:200, for 30 min
at room temperature. After incubation for 10 min with
biotinylated secondary antibodies, they were incubated
with an avidin biotin complex enzyme solution for 45
min, and DAB was applied as the chromogen for 5 min
and hematoxylin was used for counter staining. Negative
controls were performed by replacing both galectin-3 and
Bcl-2 with PBS.
2.4. Histochemistry for lectins
Specimen sections with a thickness of 4 µm were
deparaffinized in xylene and rehydrated in graded alcohol
(70%–100%). Slices were treated with 0.1% (w/v) trypsin
solution for 2 min at 37 °C followed by a 0.3% methanolH2O2 solution for 30 min. After washing 3 times with PBS,
the tissues were conjugated with 2% BSA (Sigma) for 30 min
to prevent nonspecific binding and then were incubated
separately with EEL (B-135), GSL I (L-1100), and RCA I
(BA-0084) lectins (Vector, UK), each diluted to 1:200, for
1 h at room temperature. DAB was used as the chromogen
and hematoxylin was used for counterstaining. Negative
controls were performed by replacing the lectins with PBS.
2.5. Semiquantitative evaluation
Sections were semiquantitatively evaluated for TUNEL,
Bcl-2, galectin-3, and lectin (EEL, GSL I, and RCA
I) localization using a light microscope and selected
areas were photographed. HSCORE values of TUNEL,
Bcl-2, galectin-3, and lectin staining were scored in a
semiquantitative manner and included both intensity
and staining distribution patterns. Three different fields
of each slide at 200× magnification were evaluated for
immunohistochemical staining. Values were recorded as
percentages of positively stained target cells in each of 4
intensity categories as follows: no staining (-); weak staining
(+); moderate staining (++); strong staining (+++). For
each tissue, an HSCORE value was derived by adding the
percentages of cells that stained at each intensity category
and multiplying that value by the weighted intensity of
the staining using the formula HSCORE = Σ (I × PC),
where I is the intensity score and PC is the corresponding
percentage of the cells (5,6).
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2.6. Statistical analysis
Data were analyzed using the Kolmogorov–Smirnov test
and were not distributed normally; therefore, results were
presented as medians with minimum–maximum values.
For statistical analysis, the Wilcoxon matched-pairs
signed-rank test was used with IBM SPSS Statistics 20
(IBM Corp., USA). P < 0.05 was accepted as significant.
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3. Results
3.1. Clinical results
Clinical examination of the animals revealed
serosanguineous-hemorrhagic exudate oozing from the
vulva. The masses were located in the posterior vagina
and protrusion of these masses was easily noticed upon
examination of the vulva. The vulva bulged outwards
in most cases because of the masses. Tumors had the
characteristic appearance of transmissible venereal tumors
(TVTs): cauliflower-shaped nodules of various sizes (0.5–6
cm in diameter), including ulcerated surfaces.
Complete tumor regression was observed in all cases
after 2 to 7 injections (mean: 3.65 ± 0.29) of vincristine.
In the second week after the first injection of vincristine,
bleeding ceased and regression of tumor size was noticed.
Tumors were clearly reduced in the third week after the
second injection.
Leucopenia (13/20, 65%), neutropenia (3/20, 15%),
lymphocytosis (5/20, 25%), thrombocytopenia (7/20,
35%), erythropenia, hemoglobinemia, and decreased PCV
(8/20, 40%) values were observed in the vincristine-treated
animals. The most common anemia type was normocyticnormochromic, noted in 5 cases, followed by 3 cases of the
microcytic-normochromic type. Anorexia (7/20, 35%),
diarrhea (3/20, 15%), weight loss (3/20, 15%), and generalized
alopecia (8/20, 40%) were observed in some animals.
The cytological examination of the smears confirmed
tumor cells as well as vaginal epithelial cells, erythrocytes,
bacterial cells (in a few cases),aneutrophils, and lymphocytes.
TVT cells had round-to-ovoid hyperchromatic nuclei,
marginal chromatin, and large, centrally located nucleoli.
The cytoplasm was moderate in amount and eosinophilic.
Bacteria, neutrophils, and erythrocytes were observed in
smear samples taken from tumors with ulceration and
superficial hemorrhage.
3.2. Laboratory results
TUNEL, Bcl-2, galectin-3, and lectin (EEL, GSL, RCA-1)
staining shown by the corresponding HSCORE values in
the treatment and control groups are given in the Table.
3.2.1. Apoptosis
The HSCORE value was higher in treated tumor cells than
in untreated cells (Figure 1). Staining was intracytoplasmic
and positive-stained cells were distributed randomly
(Figures 2a and 2b) in both groups. Although the TUNEL
HSCORE value of the treated group was 2.09-fold higher
than in untreated tumors, there were no statistically
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Untreated CVTV

Treated CVTV

Figure 1. TUNEL HSCORE values in treated and untreated cells.

a

b

b
Figure 2. Intracytoplasmic stained positive cells showing lower
scoring after treatment (b) compared with untreated tumor cells
(a). IHC 10× original magnification, DAB chromogen.

significant differences between the groups (P < 0.675;
Table).
3.2.2. Galectin-3
Galectin-3 was significantly decreased (HSCORE median:
42.5 vs. 4) in cells from treated TVT tumors compared
to untreated tumors (Figure 3). Expression was found
predominantly in the cytoplasm in both groups, with
frequent localization at the superficial surface of TVT
tumoral cells. Galectin-3 labeling was stronger in untreated
tumor cells compared to treated tumor cells (Figures 4a
and 4b).
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Table. Medians with minimum–maximum values of HSCOREs of TUNEL, Bcl-2, galectin-3, and lectin
staining in tumor samples prior to the first vincristine treatments (controls) and tumor tissue after first
week vincristine treatments. Bold numbers in P-value column are ≤0.05.
N

Before

After

P-value

TUNEL

39

6 (0–210)

6 (1–270)

0.675

BCL-2

18

90 (60–240)

50 (20–180)

0.030

GAL-3

18

42.5 (5–120)

4 (1–100)

0.007

EEL

18

0 (0–80)

15 (0–300)

0.030

GSL

18

105 (20–240)

180 (30–300)

0.002

RCA

18

50 (5–300)

65 (20–210)

0.678

3.2.3. Bcl-2
The control group had higher HSCORE values than
the treated group, reflecting higher Bcl-2 antiapoptosis
activity (Figure 5). After the first week of treatment, the
Bcl-2 HSCORE was reduced 2.25-fold (P < 0.03). Bcl-2
labeling showed an intracytoplasmic pattern in tumor
cells. The distribution of Bcl-2 staining varied from limited
to widespread in microscopic areas in both groups. Strong
positive Bcl-2 immunoreactivity was seen in untreated
TVT cells and was also noted in blood vessels in the
treated TVT group (Figures 6a and 6b).

50
40
30
20
10
0

Untreated CVTV

Treated CVTV

Figure 3. Decreased galectin-3 in treated TVT tumoral cells.

a

b

3.2.4. Lectins
Lectin HSCORE values are shown in Figure 7. In lectin
staining, galactose-specific Euonymus europaeus lectin
(EEL) was not stained in untreated TVT tumors but was
stained remarkably in TVT cells following vincristine
sulfate treatment (Figures 8a and 8b). Tumor cells were
stained intracytoplasmically with lactose-specific Ricinus
communis agglutinin-I (RCA-I) (Figures 9a and 9b). After
vincristine sulfate treatment, the RCA-I HSCORE value
index was increased 1.3-fold. The N-acetylgalactosamine–
specific Griffonia simplicifolia lectin-I (GSL-I) HSCORE
value increased 1.7-fold after vincristine sulfate treatment.
The staining pattern was intracytoplasmic and was
primarily observed close to the outer edge of the tumor
in the untreated group, whereas the distribution of the
staining pattern was scattered all around the section
(Figures 10a and 10b) in the treated group.
Bcl-2

120
100
80
60

b
Figure 4. Strong staining with galectin-3 in untreated tumor
cells (a) compared to treated tumor cells (b). IHC 20× original
magnification, DAB chromogen.
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Figure 5. Bcl-2 HSCORE values reflecting antiapoptosis.
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b

b

a

a

b

b

Figure 6. Strong Bcl-2 immunoreactivity in untreated TVTs (a)
and positive reaction in treated tumor blood vessels (b). IHC 40×
original magnification, DAB chromogen.

Figure 8. EEL was not stained in untreated TVT tumors (a) but
was remarkably stained in TVT cells treated by vincristine sulfate
(b). IHC 4× original magnification, DAB chromogen.

200
180
160
140

Untreated CVTV
Treated CVTV

120
100
80
60

a

40

b

20
0

EEL

RCA

GSL

Figure 7. Lectin (EEL, RCA-I, and GSL-I) HSCORE values.

4. Discussion
CTVT, also known as infectious sarcoma, venereal
granuloma, transmissible lymphosarcoma or Sticker
tumor, is a mostly benign
a reticuloendothelial tumor,
usually transmitted during coitus, that occurs in young,
sexually mature, and intact dogs. It primarily affects the
external genitalia, though it is sometimes found in the
internal genitalia as well (3). Treatment protocols include

b
Figure 9. Intracytoplasmic RCA-I staining, where untreated
tumor cells (a) have higher HSCORE values than do treated
tumors (b). IHC 10× original magnification, DAB chromogen.
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a

b

b
Figure 10. Intracytoplasmic GSL-I staining, where treated tumor
cells (b) have higher HSCORE values than do untreated tumors
(a). IHC 20× original magnification, DAB chromogen.

surgery, radiotherapy, immunotherapy, biotherapy, and
chemotherapy. Surgery has been used extensively for
the treatment of small, localized CTVTs, although the
recurrence rate is as high as 50%–68% in cases of large
invasive tumors (3). Contamination of the surgical site with
CTVT cells is also a source of recurrence (7). Chemotherapy
using vincristine sulfate has been shown to be the most
effective and practical therapy. Vincristine is administered
weekly at a dose of 0.5 to 0.7 mg/m2 of body surface area
or 0.025 mg/kg, intravenously. The healing of the lesions
is gradual, although it is particularly noticeable and
significant at the beginning of the treatment (8). Complete
regression usually takes 2 to 8 treatments and occurs in
more than 90% of the treated cases with vincristine sulfate
(6,9,10). The recovery rate is approximately 100% in cases
with tumor diagnosis in the initial stages, particularly in
cases of less than 1 year of duration (7). In the present cases,
tumors were treated with 7 weeks of vincristine sulfate
application with complete regression of the tumor from
the genital sites. During the regressive stages of the tumor,
the host immune response may play a role in the variable
duration of the treatment required (from 2 to 8 weeks).
Özalp et al. (6) reported that TUNEL reactions in control
tissue samples prior to vincristine sulfate applications were
clearly less than those of the samples from treated animals
and that the differences between samples from the control
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and 2 treatments were statistically significant. However,
there were no differences between 2 treatments within a
treated group. In this study, the TUNEL HSCORE was
higher in the treatment group than in the untreated group,
although no statistical differences between the groups
were recorded. The increasing rates in TUNEL HSCORE
showed that weekly regular chemotherapy with vincristine
sulfate for CTVT treatment stabilized the inhibition of
tumor growth (6). This result is in accordance with our
study and it was observed that apoptosis began with the
first administration of vincristine sulfate.
Bcl-2 and Bax are 2 members of the Bcl-2 gene
family that play a prominent role in the regulation of
apoptosis. Bcl-2 is an intracytoplasmic and membraneassociated apoptosis suppressor (antiapoptotic protein)
gene that is found in human and canine cells, and its
overexpression is closely associated with the survival
of malignant tumors, in particular their aggressive
behavior and poor prognosis (11,12). Apoptosis is
triggered by the release of proapoptotic molecules from
the mitochondria by multiple mechanisms, including
maintenance of mitochondrial membrane integrity and
binding to proapoptotic members of the Bcl-2 family (13).
It has been observed that hormonal estrogen receptors are
significantly associated with overexpression of Bcl-2 and
mutant p53 in malignant transformation of breast tumors
(14). Jeon and Yoon (11) reported heterogeneously strong
expressions of Bcl-2 in dysplastic bile ducts, but negativeto-weak immunoreactivity in normal and hyperplastic
small bile ducts. In addition, the expression of Bcl-2
significantly increased by 85% in premenopausal patients
compared to postmenopausal breast tumors. Bcl-2 has
been shown to repress cell death triggered by a diverse
array of stimuli, including chemotherapy and gamma
irradiation. Rui et al. (3) stated that upregulated expression
of the antiapoptotic Bcl-2 protein in tumor cells differs
depending on the malignancy and treatment regimens
and might be related to chemotherapy resistance in feline
tumors. Red deposits in the cytoplasm of positive cells
were demonstrated by immunohistochemical analysis of
Bcl-2 in CTVT samples (1). A high concentration of the
antiapoptotic protein Bcl-2 might allow cells promoting
mutations to survive by evading apoptosis. The Bcl-2
protein is overexpressed in CTVT samples independent
of the stage of tumor development and the contribution
of Bcl-2 in carcinogenesis remains puzzling because its
expression can be associated with resistance to drugs and
radiotherapy. The role of Bcl-2 in CTVT may suggest a
mechanism for tumor cell survival for a period of time,
closely related to exogenous tissue (1). In the present study,
the immunohistochemical Bcl-2 expression was higher in
untreated tumor cells and was reduced after vincristine
treatment. Increased endothelial staining in the treated
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group might indicate that CTVT has upregulated synthesis
of and resistance to Bcl-2 to protect from apoptosis. It has
been suggested that vincristine sulfate downregulates Bcl-2
expression after the first treatment and this downregulation
protects from apoptosis. Although there was significant
downregulation in Bcl-2 after the initial treatment, there
was insignificant upregulation of apoptosis in treated
CTVT. Therefore, further studies should be conducted to
clarify the mechanisms and routes that downregulate Bcl2 in CTVT.
Galectin-3, which plays a vital role in cell differentiation,
proliferation, adhesion, cell-cell and/or cell-extracellular
matrix interactions, cell spread, and tumor cell apoptosis,
is a member of a family of multifunctional β-galactoside–
binding lectins (15–17). Although galectin-3 is widely
expressed in normal and tumor cells (18,19), its
overexpression or downregulation is controversial in
tumor malignancies (15). The metastatic potential of
colon tumor cell lines and malignant nonmedullary
thyroid neoplasms were directly related to the expression
of galectin-3 (4,20), while human colon cancer (21,22) as
well as mammary cancer in human and canine requires
downregulation of galectin-3 for progression (16,23).
Choi et al. (15) and de Oliveira (16) clearly demonstrated
that galectin-3 was overexpressed in adenoma but not in
adenocarcinoma and that low expression of galectin-3
was associated with canine mammary tumor progression.
In contrast, high expressions of galectin-3 in invasive
neoplastic cells in canine gastric carcinoma suggested an
important role in metastasis (24). In this study, CTVTs
were intracytoplasmically stained with galectin-3 in
both groups. Galectin-3 was expressed in the CTVT
control group but sharp downregulation was observed in
treated cells after vincristine sulfate administration. This
decrease is compatible with the result of Choi et al.’s study
(15) because CTVT usually remains local and does not
metastasize. Vincristine might be responsible for thwarting
antiapoptotic effects. It has been speculated that subcellular
distribution of galectin-3 might be responsible for
increasing apoptosis resistance of tumor cells (16). CTVT
cells with decreased staining of galectin-3 may be more
susceptible to apoptosis after vincristine sulfate treatment.
It has been thought that galectin-3 overexpression is
phenotypically associated with malignant transformation
and progression toward metastatic potential (4,16).
Moreover, galectin-3 is a chemoattractant to endothelial

cells, and it stimulates angiogenesis and provides an escape
route by which cells can leave the primary tumor and
enter into blood circulation (25,26). Because decreased
galectin-3 expression would lead to reduced adhesiveness
between tumor cells and facilitate cancer cell invasion (16),
vincristine sulfate might be helpful for downregulation of
galectin-3 to prevent malignant forms and metastases.
Lectins are specific carbohydrate-binding proteins
(27). They have a significant role in identifying cellular
carbohydrate residues. Different biological functions in
animals are attributed to lectins, including regulation of
cell adhesion and glycoprotein synthesis. Pluripotent
stem cells had the specific glycan structure recognized by
EEL multipotent cell types (28). GSL-I has been reported
to bind several glycoproteins, including laminin, and is
necessary for intercellular communication (29). RCA1 histochemical staining was found to be negative in the
normal central nervous system. However, benign tumors
like astrocytoma, medulloblastoma, ependymoma, and
oligodendroglioma were stained with RCA-1. Moreover,
RCA-1 staining was decreased in malignant tumors such
as neurocytoma and malignant astrocytoma (27). In this
study, RCA-1 staining scores increased after treatment, as
is seen in benign tumors. Increased RCA-1 staining after
treatment might be related in that CTVT cells were subject
to apoptosis. After treatment, HSCORE values showed
increasing rates in all 3 of the lectins examined (EEL,
GSL-1, and RCA-1). A significant outcome was observed
in this study. Because CTVT cells occurred discretely
or in sheets and have loose connective tissue, the tumor
can easily spread from site to site and from dog to dog by
direct contact with the mass. During the treatment period,
minimal tumor spread and fewer malignancies might be
related to increased lectins, which regulate cell-to-cell and
cell-to-matrix adhesion.
In summary, increased apoptosis and lectin-binding
rates and decreased expression of the antiapoptotic factors
Bcl-2 and galectin-3 were observed after vincristine
sulfate treatment of CTVTs. These results show that the
expression of galectin-3, Bcl-2, and certain lectins (EEL,
GSL-1, and RCA-1) are related to CTVT regression after
treatment with vincristine sulfate.
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